Stockscreener 앱 받기
2.73
5.86%
-0.17
시간 외 거래:
2.73
전일 마감가:
$2.90
열려 있는:
$2.9
하루 거래량:
1.05M
Relative Volume:
0.80
시가총액:
$385.36M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-7.80
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
-12.22%
1개월 성능:
-11.36%
6개월 성능:
+80.79%
1년 성능:
+43.68%
1일 변동 폭
$2.60
$3.0169
1주일 범위
$2.60
$3.19
52주 변동 폭
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.73 | 385.36M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq
Compass stock gains amid Guggenheim buy rating - MSN
Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ) - Seeking Alpha
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Compass Therapeutics: Good Execution, Major Catalysts Ahead (NASDAQ:CMPX) - Seeking Alpha
Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target -February 24, 2025 at 07:24 am EST - Marketscreener.com
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler - MarketBeat
Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer - The Globe and Mail
Piper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight Recommendation - Nasdaq
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Compass Therapeutics at Overweight -February 19, 2025 at 09:07 am EST - Marketscreener.com
Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView
Piper Sandler sets $12 target on Compass Therapeutics stock By Investing.com - Investing.com UK
Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline - TipRanks
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat
Chronic Pulmonary Hypertension Market Expected to rise, 2034 | COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Trading Down 7.6%Here's Why - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Leerink Partnrs Has Strong Outlook for CMPX FY2024 Earnings - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by Bleakley Financial Group LLC - Defense World
Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow - The Globe and Mail
Organon (OGN) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Molson Coors (TAP) Q4 Earnings: What To Expect - The Globe and Mail
Procter & Gamble Co: Rising -7.15% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):